Literature DB >> 9074373

Single catheter technique of hepatic venous isolation and extracorporeal charcoal hemoperfusion for malignant liver tumors.

Y Ku1, T Fukumoto, M Tominaga, T Iwasaki, I Maeda, N Kusunoki, H Obara, M Sako, Y Suzuki, Y Kuroda, Y Saitoh.   

Abstract

BACKGROUND: A single catheter technique of hepatic venous isolation and charcoal hemoperfusion (HVI-CHP) using a 4-lumen/2-balloon (4L-2B) catheter was developed to perform high-dose intra-arterial chemotherapy of the liver. Herein we report the technique, safety, and pharmacokinetics of this system in comparison with the original double-balloon technique. PATIENTS AND METHODS: Sixteen patients with malignant liver tumors were treated by hepatic arterial infusion (HAI) with adriamycin at a dose of 100 mg/m2 under HVI-CHP. Seven patients underwent HVI-CHP by the double-balloon technique (group A), in which filtered hepatic effluent and the rest of the inferior vena caval blood were separately drawn and returned to the left axillary vein. The other nine patients were treated by the single catheter technique (group B). In group B, hepatic effluent was isolated by balloon inflations and directed to filters through fenestrations of one major lumen of a 4L-2B catheter. The filtered blood was returned straight to the right atrium through the other major lumen of the catheter.
RESULTS: All patients in group A had a smooth stepwise induction of HVI-CHP, whereas one of nine patients in group B developed severe hypotension requiring interruption of HVI. The hepatic venous flow rate in group B during HVI-CHP was significantly higher than that in group A (P < 0.05). Systemic adriamycin exposure, as assessed by the area under the time concentration curve in systemic serum, was significantly higher in group A compared to that in group B (P < 0.01).
CONCLUSIONS: The single catheter technique is hemodynamically tolerable and feasible in the majority of patients with malignant liver tumors. In view of systemic drug exposure, the single catheter technique is superior to the original double-balloon technique.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074373     DOI: 10.1016/S0002-9610(96)00422-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion.

Authors:  Y Ku; T Iwasaki; T Fukumoto; M Tominaga; S Muramatsu; N Kusunoki; T Sugimoto; Y Suzuki; Y Kuroda; Y Saitoh; M Sako; S Matsumoto; S Hirota; H Obara
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

2.  New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch.

Authors:  Takumi Fukumoto; Masahiro Kido; Atsushi Takebe; Motofumi Tanaka; Hisoka Kinoshita; Kaori Kuramitsu; Shohei Komatsu; Daisuke Tsugawa; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2017-03-21       Impact factor: 2.549

3.  Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.

Authors:  Yonson Ku; Takeshi Iwasaki; Masahiro Tominaga; Takumi Fukumoto; Tetsuya Takahashi; Masahiro Kido; Satoshi Ogata; Masanori Takahashi; Yoshikazu Kuroda; Shinichi Matsumoto; Hidefumi Obara
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

4.  Cryotherapy for liver metastases.

Authors:  Malgorzata M Bala; Robert P Riemsma; Robert Wolff; Michal Pedziwiatr; Jerzy W Mitus; Dawid Storman; Mateusz J Swierz; Jos Kleijnen
Journal:  Cochrane Database Syst Rev       Date:  2019-07-10

Review 5.  Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies.

Authors:  Mark C Burgmans; Eleonora M de Leede; Christian H Martini; Ellen Kapiteijn; Alexander L Vahrmeijer; Arian R van Erkel
Journal:  Cardiovasc Intervent Radiol       Date:  2015-12-30       Impact factor: 2.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.